Enhanced expression of interleukin-6 in bone and serum of metastatic renal cell carcinoma

Human Pathology

Volumn 29, Issue 4, 1998, Pages 421-424

  Paule, Bernard ^a   Clerc, Didier ^b   Rudant, Christiane ^b   Coulombel, Colette ^b   Bonhomme Faivre, Laurence ^b   Quillard, Jeanine ^b   Bisson, Michel ^b  

^a BICÊTRE HOSPITAL   (France)

^b NONE

Author keywords

Bone metastasis; Immunohistochemistry; Interleukin 6; Renal cell carcinoma

Indexed keywords

DEXAMETHASONE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PAMIDRONIC ACID; RECOMBINANT ALPHA2A INTERFERON; RETINOIC ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE LEVEL; BONE METASTASIS; CANCER RADIOTHERAPY; CASE REPORT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; PROTEIN EXPRESSION; SACRUM; SERUM; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031798846     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90128-9     Document Type: Article

References (23)

1. Kishimoto T: The biology of interleukin-6. Blood 74:1-10, 1989
2. Tsukamoto T, Kumamoto Y, Miyao N, et al: Interleukin-6 in renal cell carcinoma. J Urol 148:1778-1782, 1992
3. Koo AS, Bochner B, deKermion JB, et al: Production and regulation of interleukin-6 by renal cell carcinoma in vitro: Protein activity and mRNA gene expression. Surg Forum 41:710-713, 1990
4. Takenawa J, Yoshiyuki K, Fukumoto M, et al: Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst 83:1668-1672, 1991
5. Miki S, Iwano M, Miki Y, et al: IL-6 functions as an autocrine growth factor in renal carcinoma. FEBS Lett 250:607-610, 1989
6. Blay JY, Bolon J, Alberte I, et al: Growth inhibition of renal carcinoma cell lines by interleukin-6 antisense oligonucleotides: An internal autocrine loop. Proc AACR 35:3357, 1994 (abstr)
7. Blay JM, Negrier S, Combaret V, et al: Serum level of interleukin-6 as a pronostic factor in metastatic renal cell carcinoma. Cancer Res 52:3317-3322, 1992
8. Paule B, Bonhomme Faivre L, Rudant C, et al: Interferon alpha 2a plus tretinoin in patients with metastatic renal carcinoma: A pilot study. Am J Health Syst Pharm 54:190-192, 1997
9. Weissglas M, Schamhart DHJ, Lowik C, et al: Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal carcinoma implanted into nude mice. J Urol 153:854-857, 1995
10. Weissglas M, Schamhart DHJ, Clemens WGM, et al: The role of interleukin-6 in the induction of hypercalcemia in renal cell carcinoma transplanted into nude mice. Endocrinology 138:1879-1885, 1997
11. Black K, Mundy GR, Garret IR: Interleukin-6 causes hypercalcemia in vivo and enhances the bone resorbing potency of interleukin-1 and tumor necrosis factor by two orders of magnitude in vitro. J Bone Min Res 5:787-793, 1990
12. Lichtenstein A, Berenson J, Norman D, et al: Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 74:1266-1273, 1989
13. Lu ZY, Bataille R, Poubelle P, et al: An interleukin-1 receptor antagonist (IL-IRA) blocks the IL-1 induced IL-6 paracrine production through a prostaglandin-E2 (PGE2)-related mechanism in multiple myeloma. Stem Cells 13:28, 1995 (suppl 2)
14. Barille S, Collette M, Bataille R, et al: Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but down regulate osteocalcin. Blood 86:3151-3159, 1995
15. Lust JA, Kline MP, Ahman GJ, et al: Correlation of IL-1β mRNA expression with osteolytic disease and IL-6 mRNA expression with labelling index in plasma cell dyscrasias. Blood 80:468, 1992 (suppl 1)
16. Yasukawa K, Saito T, Fukunaga T, et al: Purification and characterization of soluble human IL-6 receptor expressed in CHO cells. J Biochem 108:673-676, 1990
17. Dubois C, Schlageter MH, De Gentile A, et al: Modulation of IL-6 and IL-1b and G CSF secretion by all trans retinoic acid in acute promyelocytic leukemia. Leukemia 8:1750-1747, 1994
18. Passeri G, Girasole G, Uliette V, et al: Bisphophonates inhibit IL-6 production by human osteoblastic cells MG 63. J Bone Miner Res B2:S230, 1994 (suppl 1)
19. Sasaki A, Boyce BF, Story B, et al: Biphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55:3551-3557, 1995
20. van der Puijm G, Vloedgraven H, van Beck E, et al: Biphosphonates inhibit the adhesion of breast cancer cells to bone matrix in vitro. J Clin Invest 98:698-705, 1996
21. Berenson JR, Lichenstein A, Porter L, et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Eng J Med 334:448-493, 1996
22. Hortobagy GN, Theriaut RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications with breast cancer and lytic bone metastases. N Engl J Med 335:1785-1791, 1996
23. Takenawa J, Kaneko Y, Okumura K, et al: Inhibitory effect of dexamethasone and progesterone in vitro on proliferation of human renal cell carcinomas and effects on expression of interleukin-6 or interleukin-6 receptor. J Urol 153:858-862, 1995